French pharmaceutical company Servia as well as generic producers including Israel’s Teva received formal objections from the European Commission concerning alleged entry delay of the generic form of cardiovascular drug perindopril. By both buying up rare technology needed to create the drug and settling out of court with would-be generic producers, the Commission believes Servier abused its dominant market position by restricting competitive business. Similar pay-for-delay practices were denounced only a few days ago in the Commission’s objections issued to pharmaceutical powerhouse Lundbeck.
Featured News
Epic Games Drops Suit Against Samsung in Antitrust Case, Google Remains in Crosshairs
Jul 7, 2025 by
CPI
Former FTC Antitrust Leader Returns to Covington & Burling in Leadership Role
Jul 7, 2025 by
CPI
SEC Issues New Guidance for Disclosing ETPs
Jul 7, 2025 by
CPI
AI Company Buys Bitcoin Miner in $9 Billion Deal to Expand Data Power
Jul 7, 2025 by
CPI
Turkey’s Competition Regulator to Use AI to Combat Algorithmic Price Fixing
Jul 7, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – eDiscovery & Antitrust
Jun 30, 2025 by
CPI
Off-Channel and Ephemeral Messaging in Antitrust Investigations: Legal Risks, Regulatory Focus, and Ediscovery Challenges
Jun 30, 2025 by
Daniel Rupprecht & Tristan Jenkinson
Encrypted Messaging in the Crosshairs: Compliance, Legal Risks, and Global Perspectives
Jun 30, 2025 by
Corey Bieber & Guillermo Christensen
Ephemeral and Encrypted Messaging: DOJ Expectations, Compliance Risks, and Best Practices
Jun 30, 2025 by
Megan Gerking, Joe Folio, Haydn Forrest & Adrienne Irmer
Antitrust Litigation in the Age of GenAI
Jun 30, 2025 by
Robin Perkins & Tom Gricks